Literature DB >> 27010647

Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment.

A Monegal1, P Peris2, M Alsina3, J Colmenero4, N Guañabens2.   

Abstract

Non-uremic calciphylaxis is a severe rare disorder characterized by ischemic necrosis. Recently, three cases of cutaneous calciphylaxis have been described in the context of teriparatide treatment. We present a 51-year-old woman with alcoholic cirrhosis who developed multiorganic calciphylaxis shortly after starting teriparatide treatment associated with calcium and 25-hydroxyvitamin D supplements for severe osteoporosis. After lengthy care of the infectious complications and treatment with bisphosphonates and sodium thiosulfate progressive improvement was observed over a 3-year period. The time between the initiation of teriparatide and the development of calciphylaxis suggests that this agent may have been the triggering factor of this process. Nevertheless, other non-negligible risk factors for calciphylaxis such as alcoholic liver disease, obesity, and vitamin D treatment must also be considered in this patient. Considering the severity of this extremely rare clinical condition, better knowledge of the risk factors related to calciphylaxis development is mandatory.

Entities:  

Keywords:  Calciphylaxis; Multiorganic; Non-uremic; Teriparatide; Vitamin D

Mesh:

Substances:

Year:  2016        PMID: 27010647     DOI: 10.1007/s00198-016-3571-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  15 in total

1.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Authors:  Y L Ma; R L Cain; D L Halladay; X Yang; Q Zeng; R R Miles; S Chandrasekhar; T J Martin; J E Onyia
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

Review 2.  Evolution of treatment strategies for calciphylaxis.

Authors:  Edward A Ross
Journal:  Am J Nephrol       Date:  2011-10-06       Impact factor: 3.754

3.  Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.

Authors:  José V Torregrosa; Carlos E Durán; Xoana Barros; Miquel Blasco; Marta Arias; Aleix Cases; Josep M Campistol
Journal:  Nefrologia       Date:  2012-05-14       Impact factor: 2.033

4.  Calciphylaxis: natural history, risk factor analysis, and outcome.

Authors:  Roger H Weenig; Lindsay D Sewell; Mark D P Davis; James T McCarthy; Mark R Pittelkow
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

5.  Breast necrosis: calciphylaxis a rare cause.

Authors:  Joseph J Thornton; James Dolph
Journal:  Can J Plast Surg       Date:  2008

Review 6.  Calciphylaxis: diagnosis and clinical features.

Authors:  Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

Review 7.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

Review 8.  Vascular calcification: an update on mechanisms and challenges in treatment.

Authors:  Meiting Wu; Cameron Rementer; Cecilia M Giachelli
Journal:  Calcif Tissue Int       Date:  2013-03-01       Impact factor: 4.333

9.  Sodium thiosulfate in the treatment of calciphylaxis.

Authors:  George F Cohen; Nikki S Vyas
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

10.  Pulmonary calciphylaxis associated with acute respiratory and renal failure due to cryptogenic hypercalcemia: an autopsy case report.

Authors:  Na Rae Kim; Jin Won Seo; Young Hwan Lim; Hyoung Suk Ham; Wooseong Huh; Joungho Han
Journal:  Korean J Pathol       Date:  2012-12-26
View more
  4 in total

Review 1.  Calciphylaxis.

Authors:  Sagar U Nigwekar
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-07       Impact factor: 2.894

Review 2.  Anabolic treatment for osteoporosis: teriparatide.

Authors:  Richard Eastell; Jennifer S Walsh
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

3.  Non-Uremic Calciphylaxis: An Unexpected Complication With Recombinant Human Parathyroid Hormone.

Authors:  Cory DeClue; Bhavana Chinnakotla; Michael J Gardner
Journal:  Cureus       Date:  2021-05-13

4.  A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.

Authors:  Margret Patecki; Gabriele Lehmann; Jan Hinrich Bräsen; Jessica Schmitz; Anna Bertram; Lars Daniel Berthold; Hermann Haller; Wilfried Gwinner
Journal:  BMC Nephrol       Date:  2017-04-21       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.